John Kollins, CEO, Director at Mateon Therapeutics, holds 0.00 shares in Mateon Therapeutics (Ticker: MATN), holds ― shares in Satsuma Pharmaceuticals (Ticker: STSA), holds 4.16K shares in Paratek Pharmaceuticals (Ticker: PRTK). Most recently, John Kollins ― shares of Mateon Therapeutics on ― for an estimated value of ―.
What is the percentage of profitable transactions made by John Kollins?
The percentage of profitable transactions made by John Kollins is ―.
What is the average return per transaction made by John Kollins?
The average return per transaction made by John Kollins is ―.
What stocks does John Kollins hold?
John Kollins holds: MATN, STSA, PRTK stocks.
What was John Kollins’s latest transaction?
John Kollins latest transaction was an Uninformative Buy of ―.
What was John Kollins's most profitable transaction?
John Kollins’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is John Kollins's role in Mateon Therapeutics?
John Kollins's role in Mateon Therapeutics is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.